

Buckwheat and CVD risk markers, a systematic review and meta-analysis

Liangkui Li¹, Georg Lietz¹ and Chris J. Seal^{1,2}

¹ Human Nutrition Research Centre

Institute of Cellular Medicine

Faculty of Medical Sciences

Newcastle University

Newcastle upon Tyne NE2 4hh, UK

² Corresponding author

email: chris.seal@ncl.ac.uk

telephone: +44-191-2087650

Abstract

The effects of buckwheat intake on cardiovascular diseases (CVD) have not been systematically investigated. The aim of the present study was to comprehensively summarise studies in humans and animals evaluating the impact of buckwheat consumption on CVD risk markers and to conduct a meta-analysis of relevant data. Thirteen randomised, controlled human studies, two cross-sectional human studies and twenty-one animal studies were identified. Using random effects models, the weighted mean difference of post-intervention concentrations of blood glucose, total cholesterol and triglycerides were significantly decreased following buckwheat intervention compared with controls [differences in blood glucose: -0.85 mmol/L (95% CI: -1.31, -0.39), total cholesterol: 0.50 mmol/L (95% CI: -0.80, -0.20) and triglycerides: 0.25 mmol/L (95% CI: -0.49, -0.02)]. Responses of a similar magnitude were seen in two cross-sectional studies. For animal studies, nineteen of twenty-one studies showed a significant reduction in total cholesterol of between 12 and 54%, and fourteen of twenty studies showed a significant reduction in triglycerides of between 2 and 74%. All exhibited high unexplained heterogeneity. There was inconsistency in HDL cholesterol outcomes in both human and animal studies. It remains unclear whether increased buckwheat intake significantly benefits other markers of CVD risk, such as weight, blood pressure, insulin, and LDL-cholesterol, and underlying mechanisms responsible for any effects are unclear.

Key Words

Buckwheat, CVD risk markers, meta-analysis

1. Introduction

Across the globe, cardiovascular diseases (CVD) are the leading cause of morbidity and death, and accounts for approximately one third of all deaths around the world [1]. Elevated blood pressure, raised total cholesterol, low density lipoprotein cholesterol (LDL-cholesterol) and high density lipoprotein cholesterol (HDL-cholesterol) concentrations are clinically considered as major CVD risk factors. There are increasing epidemiological studies suggesting that diets rich in whole grains are linked to a lower risk of CVD and mortality [2-6]. In China, recently changes to traditional diets, which have shown a dramatic decrease in the amount of whole grain consumption from 104 g/d in 1982 to 24 g/d in 2002 may be a contributory factor for the elevated CVD mortality in this country [6,7]. The pseudo-cereal buckwheat, which belongs to *Polygonaceae* family, is included in the "whole grain" category in the terms of nutritional value [8]. Buckwheat has been cultivated as a traditional food in China since 1000BC and is found almost everywhere globally, but mainly in the northern hemisphere, such as in Russia and China [9].

In recent years, there has been increasing interest in the use of buckwheat as a raw food material owing to its "re-discovered" nutritional value and health benefits [9,10]. Among the main nine species with agricultural significance, common buckwheat and Tartary buckwheat (also known as bitter buckwheat) are the most widely grown species [11]. Buckwheat seeds are the principle form for human consumption, and they are mainly consumed milled as flours used in bakery products (bread, noodles, snacks and cookies) enriched with buckwheat flour at levels ranging up to 60%, and in non-bakery buckwheat products (honey, tea and sprouted grains) [12]. In addition to a high starch content as an energy source, buckwheat is rich in nutritionally valuable protein with a well-balanced amino acid profile, dietary fibre, lipids and minerals, along with other health-promoting components such as phenolic compounds and sterols, which has attracted growing attention as a potential functional food [13]. Buckwheat, as a traditional Chinese foodstuff, is well known to contain high concentrations of rutin compared with other common plant foods. In addition, the absence of gluten, makes buckwheat-containing products potential alternatives for patients suffering from celiac disease [14]. It has been demonstrated that intake of buckwheat or buckwheat enriched products is associated with a wide range of health benefits, including anticancer, anti-inflammatory, hypoglycemic and hypocholesterolemic effects, although the specific bioactive components responsible for the beneficial effects of buckwheat remain uncertain [15].

To date, relatively few studies have been carried out to investigate the impact of buckwheat intake on human health. Moreover, to our knowledge, there has not been any quantitative study to systematically review and summarize the effects of buckwheat consumption on CVD risk markers. With accumulating evidence, the object of this work was to comprehensively review the recent

70 literature and carry out a meta-analysis evaluating the changes in blood glucose and lipid
71 concentrations induced by buckwheat intake in humans and animals. A secondary objective was to
72 explore possible mechanisms underlying any beneficial effects observed.

73

2. Methods

2.1. Data sources and literature search

A comprehensive literature search for prospective studies that had evaluated the correlation between buckwheat intake and CVD risk between 1960 and 2018 was undertaken. PubMed, Scopus, Ovid, EBSCO, Web of Compendex, ProQuest databases, Science, JSTOR, Medline and China National Knowledge Infrastructure were searched using the search terms ‘buckwheat’ AND ‘cardiovascular disease’ OR ‘cholesterol’ AND ‘human’ OR ‘animal’, and the same terms were applied in each database during the search phase. CVD was defined to include stroke, aortic disease, peripheral arterial disease and coronary heart disease. In addition, the reference lists of retrieved papers were searched manually for all additional potentially relevant papers. The search was restricted to studies on humans and animals and included those that were written in different languages including English or Chinese. Data were extracted by a single reviewer.

The studies included in this review met the following criteria: 1) a prospective cohort study, 2) normal laboratory animals or free living humans, 3) buckwheat-intake exposure, 4) the results included markers of CVD risk, such as plasma glucose and insulin concentrations and lipid profile. Since cholesterol was the most commonly indicator of CVD response to whole-grain foods, cholesterol was used as a primary outcome marker in this review. The eligibility criteria were set before the start of the research.

2.2. Data extraction

The following data were extracted from each human study: lead author, year of publication, characteristics of subjects, number of subjects, mean/median intake of buckwheat, types of buckwheat consumed, trial length and findings. The sample size of human studies in this review was the overall total for the experiment rather than restricting to either control or intervention diet/s. The following data were extracted from each animal study: lead author, year of publication, animal species, mean /median intake of buckwheat, experimental diet, trial length and outcomes. Missing data are reported as “Not stated” if they were not explained in the corresponding articles.

2.3. Statistical analysis

All statistical analyses were performed with STATA 12.0 (Stata Corp); $P < 0.05$ was considered significant. Heterogeneity across studies was quantified by using the I^2 statistic to consider each study design, as a quantitative evaluation of inconsistency among studies [16]. To pool the results of studies of the acute impacts on blood glucose, lipid profiles, a fixed effects models was used when heterogeneity was absent or low ($I^2 < 20\%$); when heterogeneity was greater, a random effects model was used. In this review, weighted mean differences (WMD) between treatment (buckwheat diet) and

control groups (normal or refined diet) or before and after treatment were combined via a random effects model to evaluate the size of treatment impacts on CVD risk markers, including blood concentrations of glucose, total, HDL and LDL cholesterol and triglycerides. To examine whether a single study exerted undue impact on the overall results, sensitivity analyses were performed in which each individual study was excluded from the meta-analysis and the effect size recalculated with the remaining studies. For all outcomes, *a priori* subgroup analyses were planned to be conducted with meta-regression models, if there were ≥ 10 studies. Results of the studies reported in mg/dL were converted to mmol/L using standard conversion factors, with 1 mg/dL = 0.02586 mmol/L for cholesterol, 1 mg/dL = 0.01129 mmol/L for triglycerides. These values were obtained as mean \pm SD. For continuous results, summary estimates of WMD with 95% CI were assessed for net changes between each treatment and control groups. Furthermore, potential publication bias of the studies were also evaluated by visual inspection of Funnel plots and quantitatively assessed using Begg's and Egger's tests, where $P < 0.05$ was deemed statistically significant [17].

3. Results

3.1. Study selection

As shown in Figure 1, the systematic search of the scientific databases led to the initial identification of 675 articles for further evaluation. After removing duplicate articles (239) and articles that did not meet the eligibility criteria (408), a total of 28 articles including 11 human studies and 17 animal studies were included in the review. It was noteworthy that five trials were reported in the same population; thus, this current review combined the informative data and retained only the latest paper to avoid information duplication [18-22]. Manual searching of the reference list of the relevant articles yielded 18 additional articles. After applying the inclusion criteria, 8 of these articles were considered fit to include. Consequently, the combination of electronic and manual searching resulted in 36 articles which were included in the final review. To be specific, this review pooled the results of 15 human studies, consisting of 13 short-term randomized, controlled trials (RCT) and 2 cross-sectional studies, which had the assessed lipid-lowering effects of buckwheat in free-living subjects, and 21 animal studies. Nine human studies were conducted in China, two in India and one each in Sweden, Canada, Italy and Serbia. Ten animal studies were carried out in Japan, seven in China and one each in Spain, Poland, Egypt and South Korea.




Figure 1. Flow diagram of article selection

3.2. Characteristics of studies

Extracted data from the human and animal studies are in Tables 1 and 2, respectively. All except two human cross-sectional studies in the review were RCT studies, with follow-up durations ranging from 7 days to 24 weeks in human studies and 10 days to 8 weeks in animal studies. Overall, buckwheat intake in RCT human studies ranged from 40 g to 300 g of buckwheat ingredients (median levels of individual series), with four studies the amounts consumed unstated. Participants were either healthy or had one or more CVD risk markers, including overweight, hypertension, hyperglycemia and hyperlipidemia. The methods of the included studies were similar, with a baseline period which was followed by subjects or animals being offered buckwheat or buckwheat-based products (e.g. buckwheat bread, buckwheat flour) for consumption, or placebo diets. Blood samples were obtained at baseline and after the intervention period for comparison of CVD biomarkers. Liver or faeces were only available from animal studies. With respect to the two human cross-sectional studies, since the populations started to consume fairly high amounts of buckwheat seeds as a staple food from an early

177 age, the outcomes obtained were adjudged as representing the long-term impact of buckwheat grain
178 on CVD risk markers.
179

180 **Table 1.** Summary of all human studies reviewed

Human Studies						
Source	Study population	Foodstuff; Intake	Duration	Outcomes 95% CI		
				Significant		Insignificant
Bijlani et al. (1985) [23]	healthy (n = 8 ♂)	100 g of whole BW flour	12 weeks	serum: VLDL	↓	body weight serum: TC serum: LDL serum: HDL serum: HDL/TC serum: LDL _{TG} serum: VLDL _{TG} serum: HDL _{TG} serum: TG
	healthy (n = 9 ♂)	100 g of whole BW flour	4 weeks	serum: HDL/TC serum: LDL _{TG} serum: VLDL _{TG} serum: HDL _{TG}	↑ ↑ ↑ ↓	body weight fasting blood glucose serum: TC serum: LDL serum: VLDL serum: HDL serum: TG
Bijlani et al. (1984) [24]	healthy (n = 12 ♂)	100 g of sieved BW preparation	4 weeks	serum: HDL serum: HDL/TC	↑ ↑	fasting blood glucose serum: TC serum: LDL serum: VLDL
Lu et al. (1990) [25]	patients with diabetes and hyperlipidemia (n=23,13 and 18)	BW flour	1 month	fasting blood sugar	↓	
		BW flour	1 month	serum: TC	↓	
		BW flour	1 month	serum: TG	↓	
Zheng et al. (1991) [26]	NIDDM patients (n=10 ♂, 9 ♀)	Tartary BW flour; 50g	3 months	serum: TG	↓	fasting blood glucose insulin serum: TC
Liu and Fu, (1996) [27]	patients (n=60)	Tartary BW flour; 40g/day	4 weeks	body weight systolic BP diastolic BP serum: TC serum: LDL serum: HDL serum: TG	↓ ↓ ↓ ↓ ↓ ↑ ↓	
Lin et al. (1998) [28]	Type 2 diabetes (T2DM) (n=32)	100g of Tartary BW flour	5 weeks	fasting blood glucose serum: TG	↓ ↓	serum: TC
Zhao and Guan, (2003) [29]	T2DM (n=30 ♂, 30 ♀)	BW flour	8 weeks	fasting blood glucose systolic BP serum: TC serum: HDL	↓ ↓ ↓ ↓	body weight diastolic BP serum: LDL serum: TG
Huang et al. (2009) [30]	patients with diabetes (n=18 ♂, 17 ♀)	Tartary BW mixture	2 months	fasting blood glucose HbA _{1c} % serum: TC serum: LDL serum: HDL serum: TG	↓ ↓ ↓ ↓ ↓ ↓	

181 Table 1 Continued

Wieslander et al. (2011) [31]	healthy (n = 62 ♀)	group 1: four common BW cookies (daily). group 2: four Tartary BW cookies (daily) (after 2 weeks wash-out, the groups switch type of cookies) 100 g of sieved BW preparation	6 weeks	serum: TC serum: HDL	↓ ↓	sPLA ₂
Stringer et al. (2013) [32]	healthy (n=23)	BW cracker; 76g	7 days			plasma glucose plasma: TC plasma: LDL plasma: HDL plasma: TG liver enzyme: AST liver enzyme: ALT
	T2DM (n=24)	BW cracker; 76g	7 days			plasma glucose plasma: TC plasma: LDL plasma: HDL plasma: TG liver enzyme: AST liver enzyme: ALT
Stokić et al. (2015) [33]	Patients (n=7 ♂, 13 ♀)	BW-enriched wheat bread; 300g/day	1 month	serum: TC serum: LDL liver enzyme AST liver enzyme ALT	↓ ↓	BMI systolic BP diastolic BP serum: HDL serum: TG
Yu, (2015) [34]	patients with hyperlipidemia (n=36 ♂, 24 ♀)	Tartary BW tea, 15g	60 days	serum: TC serum: LDL serum: TG	↓ ↓ ↓	systolic BP diastolic BP blood glucose serum: HDL
Dinu et al. (2017) [35]	participants with high CVD risk (n=10 ♂, 11 ♀)	group 1: BW products (daily) group 2: control products(daily) (after 8 weeks wash-out, the groups switch type of products)	24 weeks	fasting blood glucose serum: TC serum: LDL serum: TG	↓ ↓ ↓ ↓	body weight insulin serum: HDL
He et al. (1995) [36]	healthy (n=857 ♂)	BW; group 1 (n=319), 0g/day group 2 (n=207), <40g/day group 3 (n=161), 40-200g/day group 4 (n=163), >200g/day	cross-sectional study	systolic BP diastolic BP serum: TC serum: LDL serum: HDL/TC	↓ ↓ ↑ ↓ ↓	BMI serum: HDL serum: TG
Zhang et al. (2007) [18]	healthy (n=491 ♂, 470 ♀)	BW; not stated	cross-sectional study	BMI fasting blood glucose serum: TC serum: LDL serum: HDL	↑ ↓ ↓ ↓ ↑	systolic BP diastolic BP serum: TG

182 BW, buckwheat; VLDL, very low-density lipoprotein; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG,
 183 triglycerides; BP, blood pressure; HbA_{1c}, glycated hemoglobin A1c; sPLA₂, secretory phospholipase A₂; AST, aspartate transaminase; ALT,
 184 alanine transaminase.

185

186 **Table 2.** Summary of all animal studies reviewed

Animal Studies						
Source	Model	Assay product; Dose	Duration	Outcomes 95% CI		
				Significant		Insignificant
Son et al. (2008) [37]	♂ Sprague-Dawley rats	BW powder; 50% in the diets (diet with 1% cholesterol)	4 weeks	plasma: TC	↓	food intake
				plasma: LDL	↓	body weight gain
				plasma: HDL	↑	food efficiency ratio
				plasma: TG	↓	transit time
				area of lumen	↑	wall thickness
Yang et al. (2014) [38]	♂ Syrian Golden hamster	Tartary BW flour; 24% in diet (fed cholesterol diet)	6 weeks	serum: TC	↓	food intake
				serum: non-HDL	↓	body weight gain
				liver cholesterol	↓	serum: HDL
				feces: neutral sterols	↑	serum: TG
						feces: acidic sterols
Prestamo (1985) et al. [39]	♀ Wistar Hannover rats	cooked BW	30 days	body weight	↓	blood glucose
				serum: TC	↓	serum: LDL
				serum: HDL	↓	serum: TG
				HDL phospholipids	↓	liver weight
						uric acids
Orzel et al. (2015) [40]	♂ Wistar rats	buckwheat flour ,meal and bran; 200g/kg (normal diet)	4 weeks	body weight gain	↑	food intake
				serum : LDL	↓	glucose
				serum : TG	↓	serum: TC
					↓	serum: HDL
Tomotake et al. (1985) [41]	♂ Sprague-Dawley rats and ♂ ddY mice	30.7% of BWP extract in the diet (rats fed a normal or high-cholesterol diet); 54.8% of PBF (mice fed a high-cholesterol diet)	10 or 27 days	serum: TC	↓	food intake
				serum : TG	↓	body weight gain
				serum: phospholipids	↓	
				liver weight	↓	
				liver cholesterol (PBF)	↓	
				feces: dry weight (PBF)	↑	
				feces: neutral steroids	↑	
				feces: bile acids (PBF)	↑	
Magdy et al. (2014) [42]	♂ albino rats	BW hull extracts; 1000 mg/kg b. wt/day in diet (hypercholesterolemia -induced diet)	8 weeks	blood glucose	↓	plasma: HDL
				plasma: TC	↓	
				plasma: LDL	↓	
				plasma: TG	↓	
				plasma: AST	↓	
				plasma: ALT	↓	
Wang et al. (2009) [43]	♂ pathogen-free Wistar rat	Tartary BW bran extract; 0.2–1 g /kg body weight (high-fat diet)	6 weeks	serum: TC	↓	body weight gain
				serum: HDL (low dose)	↑	serum: LDL
				serum: TG	↓	
				hepatic: TC	↓	
				hepatic: TG	↓	
Hosaka et al. (2014) [44]	KK-Ay mice	common BW bran powder; 0.05 mg /g body weight	6 weeks	body weight gain	↓	food intake
				serum: TG	↓	fasting blood glucose
				liver weight	↓	insulin resistance
						serum: TC

187 Table 2 Continued

Yao et al. (2008) [45]	♂ C57BL/6 control mice and diabetic KK-Ay mice	D-Chiro-Inositol (DCI) enriched Tartary BW bran extract (TBBE); 45-182 mg of TBBE/kg in diet	5 weeks	fasting blood glucose level plasma: TG (high dose) insulin immunoreactivity	↓ ↓ ↑	body weight gain plasma: TC
Hu et al. (2015) [46]	♂ Kunming mice	D-Chiro-Inositol (DCI) enriched Tartary BW extract (DTBE); 40, 80 and 160 mg per kg body weight/day (high-fructose water)	8 weeks	body weight gain serum: glucose serum: insulin level serum: TC serum: LDL serum: HDL serum: TG liver weight serum AST and ALT activity	↓ ↓ ↓ ↓ ↑ ↓ ↓ ↓	all parameters in the group of 40 mg per kg body weight/day showed on significant effect except serum AST activity
Tomotake et al. (2000) [47]	♂ Golden Syrian Hamster	BWP extract; 381g /kg (high-cholesterol diet)	2 weeks	food intake plasma: TC plasma: HDL plasma: HDL/TC plasma: TG plasma: phospholipids liver weight hepatic cholesterol fecal dry weight feces: neutral steroids feces: acidic steroids	↑ ↓ ↓ ↑ ↓ ↓ ↑ ↓ ↑ ↑ ↑	body weight gain hepatic TG hepatic phospholipids
Tomotake et al. (2007) [48]	♂ Sprague–Dawley rats	Tartary BW flour protein and common BWP extract; 30.7% of common BWP and 43.7% of Tartary BWP in the diet (high-cholesterol diet)	27 days	serum: TC liver weight hepatic cholesterol faecal dry weight faecal excretion: nitrogen feces: neutral steroids feces: bile acids apparent protein digestibility	↓ ↓ ↓ ↑ ↑ ↑ ↑ ↓	body weight gain food intake
Tomotake et al. (2001) [49]	♂ Sprague–Dawley rats	BWP extract; 307 g/kg (normal diet)	8 weeks	plasma: TC plasma: HDL feces: neutral steroids feces: acidic steroids	↓ ↓ ↑ ↑	body weight gain food intake plasma: TG plasma: phospholipids feces dry weight
Kayashita et al. (1997) [50]	♂ Sprague–Dawley rats	BWP extract; 381 g/kg (high-Cholesterol diet)	3 weeks	plasma: TC plasma: HDL/TC plasma: TG plasma: phospholipids plasma: bile acids liver weight hepatic cholesterol hepatic: phospholipids feces dry weight feces: neutral steroids apparent protein digestibility	↓ ↑ ↓ ↑ ↓ ↓ ↓ ↓ ↑ ↑ ↓	body weight gain food intake plasma: HDL hepatic: TG feces: acidic steroids

188 Table 2 Continued

Kayashita <i>et al.</i> [52]	♂ Sprague–Dawley rats	BWP extract; 38.1%	3 weeks	plasma: TC	↓	body weight gain
				plasma: HDL/TC	↑	food intake
				plasma: TG	↓	plasma: HDL
				plasma: free fatty acid	↓	hepatic cholesterol
				plasma: phospholipids	↓	hepatic TG
				liver weight	↓	hepatic: phospholipids
				fat pad weights	↓	
Kayashita <i>et al.</i> [53]	♂ Sprague–Dawley rats	BWP extract; 381 g/kg	3 weeks	plasma: TC	↓	body weight gain
				hepatic TG	↓	food intake
				faecal dry weight	↑	insulin
				fat pad weights	↓	plasma: TG
						plasma: free fatty acid
						plasma: phospholipids
						liver weight
Kayashita <i>et al.</i> [54]	♂ Sprague–Dawley rats	BWP extract; 323.1 g/kg (high-Cholesterol diet)	3 weeks	plasma: TC	↓	body weight gain
				hepatic: weight	↓	food intake
				hepatic TC	↓	serum: TG
				hepatic TG	↑	serum: free fatty acids
						serum: glucose
Hu <i>et al.</i> [55]	♂ Kunming mice	Tartary buckwheat flavonoid fraction; 200, 400 and 800 mg per kg bw in diet (high trimethylamine-N-oxide	8 weeks	body weight gain	↓	food intake
				serum: TC	↓	water intake
				serum: LDL	↓	
				serum: HDL	↑	
				serum: TG	↓	
				liver weight	↓	
				Hepatosomatic index	↓	
Han <i>et al.</i> [56]	Wister mice	total flavones of buckwheat seeds; 2g/kg/day (high-fat diet)	10 days	serum: TC	↓	fasting blood glucose
				serum: TG	↓	
Qu <i>et al.</i> [57]	♂ Sprague–Dawley rats	high rutin in BW noodles; 980mg/kg in diet (high-fat, high-sucrose diet)	4 weeks	serum: TC	↓	body weight gain
				liver lipid	↑	feed efficiency
						serum: HDL
						serum: TG
						serum: free fatty acids
						liver TC
						dry weight of feces
Zhang <i>et al.</i> [58]	♂ Golden Syrian Hypercholesterolemia hamster	Tartary BWP extract; 353 g/kg in diet	6 weeks	plasma: TC	↓	body weight
				plasma: non-HDL	↓	fatty streak (%)
				plasma: HDL	↓	
				plasma: TG	↓	
				liver cholesterol	↓	
				total neutral sterols	↑	
				acidic sterols	↑	

189 BW, buckwheat; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides; BWP, buckwheat
 190 protein; PBF, protein buckwheat flour; AST, aspartate transaminase; ALT, alanine transaminase.

3.2. Human Studies

3.2.1. Effects on Body Weight and BMI

Body weight or BMI changed significantly in response to buckwheat consumption in two out of seven human studies but in contrasting ways (Table 3). Body weight decreased by 3.44 kg among 44 overweight participants in one of the studies by Liu and Fu, while the BMI level was higher (estimated 3%) in consumers of buckwheat than in non-consumers of buckwheat in the study of Zhang and colleagues [18,27]. The other studies observed no significant impact of buckwheat consumption on body weight or BMI.

Table 3. The number of animal and human intervention studies showing significant increase, no effect and significant reduction on markers of CVD risk

		Number of Studies		
		Significantly higher in buckwheat treatment	No effect	Significantly lower in buckwheat treatment
Human Studies				
	Body weight gain or BMI	1	5	1
	Blood pressure	—	3	3
	Blood glucose	—	5	6
	Blood insulin	—	2	—
	Total-Cholesterol	—	5	10
	LDL-Cholesterol	—	4	7
	HDL-Cholesterol	3	6	3
	Triglycerides	—	6	7
Animal Studies				
	Body weight gain	1	14	4
	Food intake	1	12	—
	Blood glucose	—	4	3
	Blood insulin	1	2	1
	Total-Cholesterol	—	2	19
	LDL-Cholesterol	—	2	5
	HDL-Cholesterol	4	6	4
	Triglycerides	—	6	14
	Liver weight	1	2	8
	Liver Total-Cholesterol	—	3	8
	Faecal weight	5	2	—
	Faecal neutral steroids	6	—	—


3.2.2. Effects on Blood Pressure

The association between buckwheat intake and blood pressure yielded inconsistent results. Of six human studies which evaluated blood pressure, He and colleagues found that in those who consumed ≥ 40 g buckwheat/day blood pressure was lower compared with those who consumed none or < 40 g/day [36]. A significant reduction was also observed in hypertensive participants in the study conducted by Liu and Fu [27]. In a further study, systolic blood pressure was significantly decreased relative to the baseline, whereas diastolic blood pressure was only slightly, and not significantly lower in type 2 diabetic subjects [29]. For the remaining three human studies, there were no significant changes in blood pressure in response to intake of buckwheat-based foods.

3.2.3. Effects on Blood Glucose and Insulin

Data on fasting blood glucose concentrations were reported in 9 randomised, controlled trials representing 548 participants based on the results of the meta-analysis. Figure 2 shows the pooled results from the random-effects model combining the weighted mean difference (WMD) for the impact of buckwheat intake on fasting glucose concentration in the total study population. The results show that the fasting blood glucose concentration was significantly decreased with buckwheat treatment in comparison with baseline or control group (WMD, -0.85 mmol/L; 95% CI: -1.31, -0.39; $P < 0.001$), with significant heterogeneity in the data ($I^2 = 94.2\%$). This finding in the present review is consistent with the result of Zhang and colleagues, who showed that fasting blood glucose concentration of people in a buckwheat-eating region of Mongolia was significantly lower (16.92%) than that of people in a non-buckwheat-eating region of the country [18]. There was no consistent effect of buckwheat on insulin concentrations reported, with a small non-significant reduction and a small non-significant increase in insulin concentrations reported in two studies [26,35].

224



225

226

227

228

229

Figure 2. Meta-analysis of the effects of buckwheat products intake on blood glucose concentration compared with baseline or control groups. Sizes of data markers indicate the weight of each study in the analysis. WMD, weighted mean difference (the results were gained from a random-effects model).

230

231

3.2.4. Effects on Lipid Profile

232

233

234

235

236

237

238

239

Results from the random-effects meta-analysis of the association between buckwheat intake and lipid parameters were shown in Figures 3, 4, 5, and 6. Compared with baseline or control arms, buckwheat consumption was associated with statistically significantly lower concentrations of total cholesterol (WMD, -0.50 mmol/L; 95% CI: -0.80, -0.20; 12 trials, 708 participates, $I^2=89.5\%$, $P= 0.001$) and triglycerides (WMD, -0.25 mmol/L; 95% CI: -0.49, -0.02; 11 trials, 592 participates, $I^2=92.5\%$, $P= 0.034$). However, there were no significant effects on LDL-cholesterol (WMD, -0.33mmol/L; 95% CI: -0.66, -0.02; 9 trials, 520 participates, $I^2=95.3\%$, $P= 0.061$) after buckwheat intake, nor on HDL-cholesterol (WMD, -0.09mmol/L; 95% CI: -0.25, -0.07; 10 trials, 642 participates, $I^2=94.4\%$, $P= 0.282$).

240

241

242

243

In the cross-sectional study of 857 Yi men conducted by He and colleagues, after multiple-regression analysis, buckwheat intake (100 g/day) was associated with significantly lower concentrations of serum total cholesterol (-0.07mmol/L, $P < 0.01$), LDL-cholesterol (-0.06mmol/L, $P < 0.05$) and a higher ratio of HDL to total cholesterol (0.01, $P < 0.05$), with no effect on HDL-cholesterol and triglycerides

[36]. These findings were in general accordance with the results from the trial by Zhang and colleagues with 961 participants, which also identified a significant decrease in HDL-cholesterol by 0.10 mmol/L ($P < 0.01$) [18].




Figure 3. Meta-analysis of the effects of buckwheat products intake on blood total cholesterol concentration compared with baseline or control groups. Sizes of data markers indicate the weight of each study in the analysis. WMD, weighted mean difference (the results were gained from a random-effects model).





Figure 4. Meta-analysis of the effects of buckwheat products intake on blood LDL cholesterol concentration compared with baseline or control groups. Sizes of data markers indicate the weight of each study in the analysis. WMD, weighted mean difference (the results were gained from a random-effects model).

259




260

261 **Figure 5.** Meta-analysis of the effects of buckwheat products intake on blood HDL cholesterol
262 concentration compared with baseline or control groups. Sizes of data markers indicate the weight of
263 each study in the analysis. WMD, weighted mean difference (the results were gained from a random-
264 effects model).

265

266



267

268 **Figure 6.** Meta-analysis of the effects of buckwheat products intake on blood triglycerides
269 concentration compared with baseline or control groups. Sizes of data markers indicate the weight of
270 each study in the analysis. WMD, weighted mean difference (the results were gained from a random-
271 effects model).

272


273 3.2.5. Sensitivity analyses and subgroups analyses

274 In sensitivity analyses, after systematically removing individual studies, the beneficial pooled effects
275 of buckwheat consumption on total cholesterol concentration were retained. However, the effect on
276 triglycerides was no longer significant after removal of the study that had the largest effect on the
277 overall result [30]. In contrast, the effect on LDL-cholesterol became statistical significant after the
278 study that had the largest negative effects on overall result was excluded (12 weeks) [23]. No effects
279 on glucose and HDL-cholesterol were observed when individual studies were removed (data not
280 shown). Subgroup analyses were planned *a priori* to investigate whether study duration, buckwheat
281 dose, types of buckwheat and study design altered the effects of buckwheat on glucose and lipid
282 profiles, but the ability to do this was effectively hindered by the small numbers of studies for each
283 trial, since meta-regression requires ≥ 10 studies per factor examined [58].

284 3.2.6. Publication bias


Funnel plot of the meta-analysis of the effect of buckwheat intake on glucose and lipid concentration were shown in Figure 7. Begg's test and Egger's test were not significant ($P > 0.05$), indicating that there was no evidence of publication bias.

288 Glucose Begg's test $P = 0.058$, Egger's test $P = 0.130$



(a)

291 TC Begg's test $P = 1.000$, Egger's test $P = 0.089$




(b)

294
295

296
297
298
299


300
301
302

LDL Begg’s test $P = 1.000$, Egger’s test $P = 0.891$




(c)

HDL Begg’s test $P = 0.474$, Egger’s test $P = 0.720$



(d)

303 TG Begg's test $P = 0.350$, Egger's test $P = 0.0080$



304
305 (e)

306 **Figure 7.** Publication bias funnel plots. Tests for publication bias of effects of buckwheat intake on (a)
307 glucose and lipid profile (b, TC; c, LDL; d, HDL; e, TG). The dash lines represent pseudo-95% Cis. P-
308 values are derived from quantitative assessment of publication bias by Begg's test and Egger's test.

309 3.3. Animal Studies

310 3.3.1. Effects on Weight Gain and Food Intake

311 This review contains nineteen animal studies which reported the impact of buckwheat intake on body
312 weight of which only four reported a significant decrease following buckwheat consumption, whereas
313 one found a significant increase in body weight by 21.66% compared with the control [40]. With
314 respect to the amounts of food consumed by the animals, food intake did not change significantly
315 compared with that of the control group in twelve out of thirteen studies, while a marked increase in
316 food intake was observed in the study by Tomotake and colleagues [47].

317 3.3.2. Effects on Blood Glucose and Insulin

318 For the studies reported here, three out of seven studies showed a significant reduction in glucose
319 concentration by between 15.20% and 18.44%, with the remaining studies showing that glucose
320 concentration was unaffected by buckwheat treatment. With respect to blood insulin, insulin
321 immunoreactivity was enhanced in one study, while a significant reduction in insulin concentration
322 was observed in another study, and the two remaining studies found no significant changes.

323

3.3.3. Effects on lipid Profile

Of the twenty-one animal studies reported here, all investigated the impact of buckwheat intake on total cholesterol and seven reported results for LDL-cholesterol. Nineteen (90.5%) of the studies observed a significant reduction in total cholesterol and five (71.4%) of the studies observed a significant reduction in LDL cholesterol; the remainder identified no significant response. The significant decrease ranged from 11.71% to 54.05% for total cholesterol and from 16.20% to 57.75% for LDL-cholesterol. HDL cholesterol level increased from 19.61% to 54.55% in four out of fourteen studies that reported this biomarker, while the level decreased (by between 11.52% and 28.37%) in another four studies. Of twenty animal studies analysing the effect on triglycerides, all studies reported that intake of buckwheat consumption resulted in a fall in the serum concentration of triglycerides, which fell significantly ($p<0.05$) from 2.27% to 73.85% in fourteen studies.

3.3.4. Other Outcomes

The liver weight of animals in this review fed buckwheat food decreased significantly from 8.49 % to 19.15% relative to the comparison group in eight out of eleven studies, while only one showed a significant increase by 5.42%. Eight of eleven studies found a reduction in liver total cholesterol content ($p<0.05$), but no significant changes were detected in the other three studies. There were significant increase in faecal weight and faecal neutral steroids by 57.58-170.97% and by 68.75-142.37% in five out of seven studies and all six studies, respectively.

4. Discussion

4.1. Effects on Body Weight

Being overweight brings about an elevated risk of health problems such as insulin resistance, type 2 diabetes mellitus, hypertension, hyperlipidemia and cardiovascular disease [59-62]. In order to evaluate the impact of buckwheat intake on body weight, the overall energy and macronutrient content in diets offered/consumed should be considered, but this was beyond the scope of this study. However, as mentioned above, there were few human and animal studies showing a significant reduction in body weight gain compared with baseline or control in response to consuming buckwheat-based food(s); restricted energy intake or intention to lose weight was not an intention of the studies reported.

Even though a significant reduction was observed in the study by Liu and colleagues, it must be noted that the participants involved in the study were overweight, and so body weight loss would not have been unexpected in an intervention study simply by engaging in the dietary intervention study itself [27]. Thus, on the basis of the published literature, it seems that the beneficial effects of buckwheat intake were not associated with weight loss, and this lack of association was consistent in both humans and animals with a variety of dietary levels of buckwheat or various forms of buckwheat products provided.

4.2. Effects on Blood Pressure

It is well known that hypertension is considered to be an important CVD risk factor, since half of ischemic heart disease and 60% of strokes cases are attributable to increased blood pressure [63,64]. One previous study revealed that 12 weeks intervention with whole grain (oats or oats plus with wheat) significantly lowered systolic blood pressure compared with a refined cereals group [65]. The effects of whole grain cereals on blood pressure, however, are inconsistent in comparison with observational data as reported by Seal and Brownlee and the paper from Tighe and colleagues is the only one to report a reduced blood pressure in a whole grain intervention that was not based on weight loss [65,66]. A significant reduction in blood pressure was only observed in one of the human studies reported here conducted by He and colleagues; these authors pointed out that water-soluble fibre, but not total dietary fibre, was independently associated with blood pressure and so an effect of buckwheat which has higher levels of soluble fibre than insoluble fibre is a possibility [36]. However, given the small number of studies carried out to date, this review is not adequately powered to conclude whether or not there are beneficial effects of buckwheat intake on blood pressure.

4.3. Effects on Blood Glucose and Insulin

Hyperglycaemia and insulin resistance are closely correlated to risk of developing CVD [67,68]. There is considerable evidence showing that whole grain intake is associated with decreased glucose concentrations and is inversely associated with insulin resistance suggesting that it is possible to regulate glucose and insulin homeostasis by cereal foods and their constituents [69-71]. Buckwheat is regarded as a low glycaemic index (GI) food, and it has been demonstrated that low-GI diets significantly improved lipid profiles in medium and long-term treatments, particularly with respect to decreasing both total and LDL cholesterol concentrations [72-74]. The results of animal studies with regard to the impact of buckwheat intake on glucose concentration, however, are conflicting, suggesting that results from animal studies do not strongly support the beneficial effects and may not be comparable to humans. In contrast, the meta-analysis of 9 clinical trials indicated that diets supplemented with buckwheat were associated with a significant 0.85 mmol/L decrease in blood glucose concentration ($p < 0.001$). Of the many possible mechanisms responsible for modulating blood glucose concentrations, buckwheat is well known for containing various bioactive phytochemicals (such as various polyphenols and d-chiro-inositol), which have been shown to positively affect either glucose or insulin metabolism in animal models [75-78]. In addition, one study showed that the presence of resistant starch in buckwheat and buckwheat products contributed to its low glycaemic index [79]. As for blood insulin, both human and animal studies yielded inconsistent results for the association between buckwheat intake and fasting blood insulin concentrations, indicating that there is no support for a beneficial effect of buckwheat on blood insulin or insulin-mediated glucose responses.

4.4. Effects on lipid Profile

Cholesterol, produced in the liver and absorbed through the diet, is essential for all animal life in normal metabolic process. However, observational epidemiologic studies reports that risk of heart attack in subjects with hyperlipidemia is 3 times higher than those in general population with normal lipid status, while a 1% reduction in serum total cholesterol is strongly correlated with a 3% decrease in CVD risk [80,81]. Thus, treatments which are aimed at reducing cholesterol concentrations are effective in decreasing death risk from stroke and coronary heart disease. Consistent with two cross-sectional studies, this meta-analysis of the RCT studies indicated that increased intake of buckwheat-based products from 7 days to 27 weeks significantly improved an individual's lipid profile, on average, decreasing total cholesterol by 0.50 mmol/L and triglycerides by 0.25 mmol/L. Moreover, the beneficial effects seen in human studies were also supported by strong evidence from animal studies. Even though the change in LDL-cholesterol concentration was not statistically different ($p = 0.061$), the data approached statistical significance, and the mean reduction was 0.33 mmol/L, and significant

decreases were also observed in two cross-sectional studies. It has been well known that a 1 mmol/L reduction of LDL-cholesterol lowers the morbidity and mortality of CVD patients by 22%, so a reduction of this magnitude could have significant clinical effects [82]. No effects of HDL-cholesterol were detected in the meta-analysis of RCT studies for buckwheat intake, in combination with inconsistent results from animal studies. The results of the meta-analysis were seen in both healthy and “at risk” subjects, but it is not possible within this review to examine differences in response between healthy and “at risk” subjects because of lack of power and the limited number of studies available. Nevertheless, it should be noted that one meta-analysis which investigated the effect of oats and oat-based products on lipid biomarkers, demonstrated that greater reductions were observed in studies where subjects initially had higher total cholesterol concentrations (>5.9 mmol/L) [83]. Thus, there was an indication that observed effects were generally more marked in subjects with higher CVD risk.

4.5. Buckwheat Intake levels

Any evaluation of health benefits associating with food products should include an attempt to define optimal amounts for human consumption. The study of Liu and Fu, described in Table 1, showed that 40 g/day Tartary buckwheat flour for 4 weeks significantly lowered total cholesterol, LDL cholesterol and triglycerides concentrations compared with baseline [27]. The dose needed to reach a significant effect was similar to that of large population-based study by He and colleagues, who found that buckwheat intake (≥ 40 g/day) was inversely related to markedly lower lipid profiles in comparison with those who consumed less than 40 g buckwheat/day [36]. Stringer and colleagues found that a higher amount of buckwheat cracker (containing buckwheat 76 g/day) for a shorter time period (7 days) did not significantly affect lipid profiles when compared with baseline, and similar results were also observed in two studies with longer intervention periods (4 and 12 weeks) by Bijlani and colleagues in 1984 and 1985 [23,24,32]. Studies showing specific amount of buckwheat used are scarce, and more well designed dose-response studies are required to confirm the minimum amounts of buckwheat needed to have a beneficial effect.

4.6. Bioactive compounds responsible for lipid-lowering activity

The lipid-lowering activity of buckwheat has been ascribed to its nutritional composition including soluble fibre, protein, rutin and quercetin. However, due to complexity of this composition, it is difficult to explore potential mechanisms underlying the beneficial effect of buckwheat on CVD risk. Some have been proposed but not fully explained, and it is possible that a combination of these components have contributed to the effects, instead of a single factor. As remarked previously, buckwheat is a good source of dietary fibre (5-11%), particularly the soluble fraction, which may help

lower total cholesterol concentrations in the body [11,84,85]. The cross-sectional study by He and colleagues demonstrated that both total dietary and water-soluble fibre from buckwheat were significantly and independently correlated with lower serum total cholesterol concentrations, even though the average cholesterol concentration was low in the study population [36]. This result was in agreement with the results showing a similar correlation between water-soluble fibre and serum total cholesterol [37]. The cholesterol-lowering effects of soluble fibre may be accounted for several mechanisms. It has been proposed that soluble fibre binds strongly to bile acids in the small intestine and elevates faecal bile acids excretion. The loss of bile acids in the stool stimulates the liver to increase cholesterol uptake from the circulation to replenish the bile acid supply. It also lowers the availability of bile acids for optimal fat digestion and absorption [86-89]. In addition, soluble fibre delays gastric emptying, slowing access of nutrients to digestive enzymes and to absorptive surfaces of the small intestine [90]. In addition, there is also emerging evidence that soluble fibre and resistant starch are additionally fermented by some bacteria in the colon, producing short-chain fatty acids (SCFA) perhaps via the inhibition of hepatic cholesterol synthesis in the liver, which helps to lower cholesterol concentrations [91,92]. One other mechanism that contributes to the cholesterol-lowering effects may be due to the low glycaemic index of buckwheat in humans with the presence of resistance starch in the cereal [79,93]. However, the hypocholesterolaemic effect of buckwheat starch, which was extracted from buckwheat flour, was not detected in rats when compared with corn starch [47].

It has been generally recognised that plant proteins may reduce plasma cholesterol concentrations, and the underlying mechanisms of the cholesterol-lowering properties of plant proteins have been extensively analysed [94-96]. However, in most studies the effect of plant dietary proteins has focused on soybean protein, leading to limited information on the influence of other plant proteins and buckwheat proteins specifically on cholesterol metabolism. Despite having a relatively low digestibility, buckwheat protein, which accounts for 10% to 12.5% of flour weight, is an excellent supplement to other common grains, as it contains a good balance of amino acids with high nutritional value [9,97-99]. Previous studies have demonstrated a potent hypocholesterolaemic activity of isolated buckwheat protein products prepared from buckwheat flour in rats or hamsters fed cholesterol-enriched or cholesterol free diets, which appeared to be stronger than that of soy protein isolate [47-53]. In one study by Kayashita and colleagues further suggested that suppressive effects on cholesterol were mediated by enhanced excretion of faecal neutral sterols and that lower digestibility of buckwheat protein products is at least in part responsible for the effect. The lower digestibility may result in lower gastrointestinal transit time, which in turn leads to a higher stool weight and greater faecal excretion of neutral sterols. It has been observed that faecal excretion of neutral sterols was inversely correlated with serum cholesterol ($r=-0.83$, $P<0.01$) [48]. Taken together,

these impacts on rats appear to be similar to the properties of dietary fibre in humans [100,101]. To demonstrate this, Kayashita and colleagues also performed another experiment showing that plasma cholesterol in rats fed intact buckwheat protein products for two weeks was significantly lower than that in rats fed trypsin-digested protein. This hypothesis has been confirmed in humans where the digestibility of buckwheat seed proteins was relatively low, owing possibly to the co-existence of phytic acid, tannins and protease inhibitors [102]. However, this contrasts with results showing that Tartary buckwheat had a reduced cholesterol-lowering impact in rats compared with common buckwheat, even though digestibility of Tartary buckwheat was lower than that of common buckwheat [48]. It is noteworthy that humans digestion is different from that of rodents, suggesting that these results should be treated with caution and more studies are required to investigate this question [103]. In addition, the strong suppression of cholesterol by buckwheat protein products could be ascribed to their effect on bile acid synthesis, and a greater excretion of faecal bile acids observed in rats, suggesting that buckwheat protein products may have bile acid-binding properties [47,49]. It has been further demonstrated *in vitro* that digestion-resistant peptides were largely responsible for bile acid binding activity of buckwheat protein digests and bile acid elimination [104,105]. In agreement with this, Zhang and colleagues very recently suggested that Tartary buckwheat protein was one of the active ingredients to decrease plasma total cholesterol concentration, mainly regulated by improving the excretion of bile acids by upregulating gene expression of hepatic CYP7A1, but also preventing absorption of dietary cholesterol by down regulating gene expression of intestinal Niemann-Pick C1-like protein 1 (NPC1L1), acyl CoA: cholesterol acyltransferase 2 (ACAT2), and ATP binding cassette transporters 5 and 8 (ABCG5/8) [57]. The composition of amino acids in dietary proteins might be another important factor influencing blood cholesterol concentration, especially the ratio of lysine to arginine, which is even lower in buckwheat protein than that of soy protein [51]. Thus, it has been speculated that cholesterol-lowering effect of buckwheat protein products observed may be ascribed to lower lysine: arginine ratio [51]. However, this hypothesis was not supported by results showing that plasma cholesterol was unaffected with the addition of arginine in the diets [50].

It is well known that Tartary buckwheat seeds are a major source of rutin and quercetin [106], with some of the quercetin identified in Tartary buckwheat seeds arising from rutin degradation [107,108]. The possibility of buckwheat rutin being one of the active components responsible for suppressive effect on cholesterol concentrations cannot be eliminated. Levels of rutin are estimated at 1.14%, a unique high flavonoid content compared with other common plant foods. Rutin has been shown to prevent the increase of plasma total cholesterol and non-HDL cholesterol in rats or mice fed with a high cholesterol or high fat diet [56,109-112]. However, in contrast to the results with rats and mice, serum total cholesterol concentrations in day-care staff were found to be lower in response to

consuming cookies prepared from common or Tartary buckwheat, but no significant differences were detected between two buckwheat groups, even though the rutin content in Tartary buckwheat seed was 30 to 150 times greater than that in common buckwheat [31,113]. It has also been suggested that the cholesterol-lowering effects seen in animal models may be partially attributable to the quercetin content in buckwheat. In animal models (rat, rabbit, and mice) fed a high-cholesterol or high-fat diet, dietary quercetin was shown to lower serum total cholesterol concentration [114-116]. However, the results regarding the effects of quercetin on cholesterol concentrations are controversial; several studies have reported that quercetin intake had no significant beneficial effects on total, LDL or HDL cholesterol and triglycerides [117-120]. The underlying mechanisms of the quercetin on lipid metabolism may be accounted for the inhibition of cholesterol synthesis in hepatocytes and also the enzyme myeloperoxidase which was shown to oxidize lipoproteins [121-123].

4.7. Sensitivity analysis

In the sensitivity analyzes, removing individual studies systematically retained the statistical significance of the effects of buckwheat on total cholesterol, supporting the stability of the observed effects, but the effect on triglycerides was no longer significant possibly due to reduced statistical power. This finding was relatively not stable to sensitivity analyze in which individuals studies were removed, thus, such analyses should be interpreted with more caution.

4.8. Limitations

Several limitations of this review should be noted. Firstly, relatively few long-term randomized and well-controlled human studies have directly investigated the effects of buckwheat intervention on risk markers for CVD, including weight gain, blood pressure, fasting blood glucose, insulin and lipids, and studies up to date have been of short duration with small sample sizes. In order to support the effects, further more large-scale human intervention studies for long-term are required. Secondly, most animal studies performed to date, have analyzed the effect of individual molecular components or various buckwheat extracts on cell lines and animal models. However, human beings consume entire buckwheat seeds (as flour in products) instead of individual extracts, producing the uncertainty whether the efficacy can be extrapolated to human health without further evaluation. Finally, the bioactive compounds responsible for buckwheat's cardiovascular health still remain uncertain, and the mechanisms underlying the effects were not fully elucidated.

5. Conclusion

In conclusion, even though the literature to date is limited and often inconsistent in study results, this review suggests that increased intake of buckwheat may lower CVD risk markers, including glucose, total cholesterol and triglycerides. Therefore, buckwheat, being a gluten-free alternative to some

common grains, such as wheat, barley and rye, deserves to be a part of our daily diet. However, it still remains unclear whether increased intake of buckwheat has significant impacts on some CVD risk markers such as body weight and LDL cholesterol. There is increasing evidence that reduction in some risk markers associated with CVD could be due to polyphenol (phytochemical), soluble fibre, protein, rutin, quercetin and other components in buckwheat, but it has not been fully elucidated which bioactive compounds are responsible for the underlying effects. Further research, especially large, well-powered, long-term human intervention studies, are required to further understand and promote the role that buckwheat seeds can play in cardiovascular health.

References

1. WHO. Diet, nutrition and the prevention of chronic diseases. Joint who/fao expert consultation. Who technical report series no. 916. Geneva: Who. **2003**.
2. Liu, S.; Stampfer, M.J.; Hu, F.B.; Giovannucci, E.; Rimm, E.; Manson, J.E.; Hennekens, C.H.; Willett, W.C. Whole-grain consumption and risk of coronary heart disease: Results from the nurses' health study. *American Journal of Clinical Nutrition* **1999**, *70*, 412-419.
3. Jacobs, D.R.; Pereira, M.A.; Kushi, L.H.; Meyer, K.A. Fiber from whole grains, but not refined grains, is inversely associated with all-cause mortality in older women: The iowa women's health study. *J Am Coll Nutr* **2000**, *19*, 326S-330S.
4. Mellen, P.B.; Walsh, T.F.; Herrington, D.M. Whole grain intake and cardiovascular disease: A meta-analysis. *Nutrition, Metabolism and Cardiovascular Diseases* **2008**, *18*, 283-290.
5. Aune, D.; Keum, N.; Giovannucci, E.; Fadnes, L.T.; Boffetta, P.; Greenwood, D.C.; Tonstad, S.; Vatten, L.J.; Riboli, E.; Norat, T. Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: Systematic review and dose-response meta-analysis of prospective studies. *Bmj-Brit Med J* **2016**, *353*.
6. Ge, K. The transition of chinese dietary guidelines and the food guide pagoda. *Asia Pac J Clin Nutr* **2011**, *20*, 439-446.
7. Critchley, J.; Liu, J.; Zhao, D.; Wei, W.; Capewell, S. Explaining the increase in coronary heart disease mortality in beijing between 1984 and 1999. *Circulation* **2004**, *110*, 1236-1244.
8. Van der Kamp, J.W.; Poutanen, K.; Seal, C.J.; Richardson, D.P. The healthgrain definition of 'whole grain'. *Food and Nutrition Research* **2014**, *58*, 1-8.
9. Li, S.Q.; Zhang, Q.H. Advances in the development of functional foods from buckwheat. *Crit Rev Food Sci* **2001**, *41*, 451-464.
10. Wu, K.; Gan, R.; Dai, S.; Cai, Y.Z.; Corke, H.; Zhu, F. Buckwheat and millet affect thermal, rheological, and gelling properties of wheat flour. *J Food Sci* **2016**, *81*, E627-E636.
11. Bonafaccia, G.; Marocchini, M.; Kreft, I. Composition and technological properties of the, flour and bran from common and tartary buckwheat. *Food Chem* **2003**, *80*, 9-15.
12. Gimenez-Bastida, J.A.; Piskula, M.K.; Zielinski, H. Recent advances in processing and development of buckwheat derived bakery and non-bakery products - a review. *Pol J Food Nutr Sci* **2015a**, *65*, 9-20.
13. Krkošková, B.; Mrázová, Z. Prophylactic components of buckwheat. *Food Res. Int.* **2005**, *38*, 561-568.
14. Saturni, L.; Ferretti, G.; Bacchetti, T. The gluten-free diet: Safety and nutritional quality. *Nutrients* **2010**, *2*, 16-34.
15. Gimenez-Bastida, J.A.; Zielinski, H. Buckwheat as a functional food and its effects on health. *J Agr Food Chem* **2015b**, *63*, 7896-7913.
16. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. *British Medical Journal* **2003**, *327*, 557-560.
17. Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* **1997**, *315*, 629-634.
18. Zhang, H.W.; Zhang, Y.H.; Lu, M.J.; Tong, W.J.; Cao, G.W. Comparison of hypertension, dyslipidaemia and hyperglycaemia between buckwheat seed-consuming and non-consuming mongolian-chinese populations in inner mongolia, china. *Clin Exp Pharmacol P* **2007**, *34*, 838-844.
19. Zhang, Y.; Ao, Y.; Tong, W.; Zhao, Y.; Zhang, H.; Yang, T.; Li, J.; Bao, J.; Wang, J.; Wang, F. Relationship between tartary buckwheat intake and hypertension and high serum lipids in mongolian people. *Chinese Journal of Hypertension* **2001**, *9*, 330-332.
20. Zhang, H.; Zhang, Y.; Lu, M.; Tong, W.; Ao, Y.; Zhao, Y.; Li, J.; Bao, J. Effects of buckwheat-eating on blood sugars and serum lipids levels and blood pressure. *Journal of Environment & Occupational Medicine* **2003**, *20*, 120-122.

- 602 21. Lu, M.; Zhang, H.; Zhang, Y.; Tong, W.; Zhao, Y.; Shan, S.; Liu, H. An epidemiological study on
603 relationship between buckwheat in diet and the prevalence rate of diabetes mellitus as well
604 as blood glucose concentration. *Modern Preventive Medicine* **2002**, *29*, 326-327.
- 605 22. Tong, W.; Wang, J.; Bu, R.B.T.; Shi, T.; Chen, W.; Feng, H.; Li, Y.; Qing, G.L.T.; Bao, J.; Zhang, Y.,
606 *et al.* Epidemiological study on relationship between taking sweet buckwheat and human's
607 blood-lipid. *China Public Health* **2002**, *18*, 1370-1371.
- 608 23. Bijlani, R.L.; Gandhi, B.M.; Gupta, M.C.; Manocha, S.; Tandon, B.N. Effect of whole buckwheat
609 (*fagopyrum esculentum*) flour supplementation on lipid profile & glucose tolerance. *Indian*
610 *Journal of Medical Research* **1985**, *81*, 162-168.
- 611 24. Bijlani, R.L.; Sud, S.; Sahi, A.; Gandhi, B.M.; Tandon, B.N. Effect of sieved buckwheat
612 (*fagopyrum esculentum*) flour supplementation on lipid profile and glucose tolerance. *Indian*
613 *Journal of Physiology and Pharmacology* **1984**, *29*, 69-74.
- 614 25. Lu, C.; Xu, J.; Zhao, P. Clinical application and therapeutic effect of composite tartary
615 buckwheat flour on hyperglycemia and hyperlipidemia. *Food Science* **1990**, *7*, 45-46.
- 616 26. Zheng, G.; Pan, X.; An, Z.; Wang, Y. Preliminary observation of lipid-decreasing effects of
617 compound tartary buckwheat flour on niddm patients. *Beijing Medical Journal* **1991**, *5*, 280-
618 280.
- 619 27. Liu, X.; Fu, X. Randomized clinical trial of tartary buckwheat's curing effect on elderly
620 hyperlipidemia. *Academic paper complies of Chinese nutrition society conference* **1996**, *7*, 184-
621 185.
- 622 28. Lin, R.; Jia, W.; Ren, J. Research and utilization of tartary buckwheat. In h. Corke & r. Lin (eds.),
623 proceeding from the international conference asian product development (pp. 187-197).
624 Shanxi, taiyuan, china: Science press. **1998**.
- 625 29. Zhao, J.; Guan, L. Effects of buckwheat flour eating for 8 weeks on blood glucose, serum lipids
626 levels and blood pressure. *Chinese Journal of Clinical Rehabilitation* **2003**, *7*, 2231-2231.
- 627 30. Huang, G.; Huang, M.; Chen, W.; Huang, Y.; Yang, Z.; You, Y. Clinical effects of tartary
628 buckwheat mixture on the treatment of early diabetic and nephropathy. *Journal of Chinese*
629 *Medicinal Material* **2009**, *32*, 1932-1935.
- 630 31. Wieslander, G.; Fabjan, N.; Vogrincic, M.; Kreft, I.; Janson, C.; Spetz-Nystrom, U.; Vombergar,
631 B.; Tagesson, C.; Leanderson, P.; Norback, D. Eating buckwheat cookies is associated with the
632 reduction in serum levels of myeloperoxidase and cholesterol: A double blind crossover study
633 in day-care centre staffs. *Tohoku J Exp Med* **2011**, *225*, 123-130.
- 634 32. Stringer, D.M.; Taylor, C.G.; Appah, P.; Blewett, H.; Zahradka, P. Consumption of buckwheat
635 modulates the post-prandial response of selected gastrointestinal satiety hormones in
636 individuals with type 2 diabetes mellitus. *Metabolism* **2013**, *62*, 1021-1031.
- 637 33. Stokic, E.; Mandic, A.; Sakac, M.; Misan, A.; Pestoric, M.; Simurina, O.; Jambrec, D.; Jovanov,
638 P.; Nedeljkovic, N.; Milovanovic, I., *et al.* Quality of buckwheat-enriched wheat bread and its
639 antihyperlipidemic effect in statin treated patients. *Lwt-Food Sci Technol* **2015**, *63*, 556-561.
- 640 34. Yu, F. Observation of the hypolipidemic effects of tartary buckwheat tea. *Journal of Today*
641 *Health* **2015**, *4*, 283-283.
- 642 35. Dinu, M.; Ghiselli, L.; Whittaker, A.; Pagliai, G.; Cesari, F.; Fiorillo, C.; Becatti, M.; Marcucci, R.;
643 Benedettelli, S.; Sofi, F. Consumption of buckwheat products and cardiovascular risk profile:
644 A randomized, single-blinded crossover trial. *Nutrition, Metabolism and Cardiovascular*
645 *Diseases* **2017**, *27*, e20-e21.
- 646 36. He, J.; Klag, M.J.; Whelton, P.K.; Mo, J.P.; Chen, J.Y.; Qian, M.C.; Mo, P.S.; He, G.Q. Oats and
647 buckwheat intakes and cardiovascular-disease risk-factors in an ethnic-minority of china.
648 *American Journal of Clinical Nutrition* **1995**, *61*, 366-372.
- 649 37. Son, B.K.; Kim, J.Y.; Lee, S.S. Effect of adlay, buckwheat and barley on lipid metabolism and
650 aorta histopathology in rats fed an obesogenic diet. *Ann Nutr Metab* **2008**, *52*, 181-187.

38. Yang, N.; Li, Y.M.; Zhang, K.S.; Jiao, R.; Ma, K.Y.; Zhang, R.; Ren, G.X.; Chen, Z.Y. Hypocholesterolemic activity of buckwheat flour is mediated by increasing sterol excretion and down-regulation of intestinal npc1l1 and acat2. *J Funct Foods* **2014**, *6*, 311-318.
39. Prestamo, G.; Pedrazuela, A.; Penas, E.; Lasuncion, M.A.; Arroyo, G. Role of buckwheat diet on rats as prebiotic and healthy food. *Nutr Res* **2003**, *23*, 803-814.
40. Orzel, D.; Zmijewski, M.; Bronkowska, M. Impact of products from ground buckwheat added to balanced diets on biochemical blood markers in wistar rats. *Rocz Panstw Zakl Hig* **2015**, *66*, 239-244.
41. Tomotake, H.; Yamamoto, N.; Yanaka, N.; Ohinata, H.; Yamazaki, R.; Kayashita, J.; Kato, N. High protein buckwheat flour suppresses hypercholesterolemia in rats and gallstone formation in mice by hypercholesterolemic diet and body fat in rats because of its low protein digestibility. *Nutrition* **2006**, *22*, 166-173.
42. Magdy, A.-A.M.S.; Sayed, A.E.-K.S.F.; Marwa, M.E.S.A.E.G. Protective effects of wheat bran and buckwheat hull extracts against hypercholesterolemia in male rats. *International Journal of Advanced Research* **2014**, *2*, 724-736.
43. Wang, M.; Liu, J.R.; Gao, J.M.; Parry, J.W.; Wei, Y.M. Antioxidant activity of tartary buckwheat bran extract and its effect on the lipid profile of hyperlipidemic rats. *J Agr Food Chem* **2009**, *57*, 5106-5112.
44. Hosaka, T.; Sasaga, S.; Yamasaka, Y.; Nii, Y.; Edazawa, K.; Tsutsumi, R.; Shuto, E.; Okahisa, N.; Iwata, S.; Tomotake, H., *et al.* Treatment with buckwheat bran extract prevents the elevation of serum triglyceride levels and fatty liver in kk-a(y) mice. *The journal of medical investigation* **2014**, *61*, 345-352.
45. Yao, Y.; Shan, F.; Bian, J.; Chen, F.; Wang, M.; Ren, G. D-chiro-inositol-enriched tartary buckwheat bran extract lowers the blood glucose level in kk-ay mice. *J Agr Food Chem* **2008**, *56*, 10027-10031.
46. Hu, Y.Y.; Zhao, Y.; Ren, D.Y.; Guo, J.J.; Luo, Y.Y.; Yang, X.B. Hypoglycemic and hepatoprotective effects of d-chiro-inositol-enriched tartary buckwheat extract in high fructose-fed mice. *Food Funct* **2015a**, *6*, 3760-3769.
47. Tomotake, H.; Shimaoka, I.; Kayashita, J.; Yokoyama, F.; Nakajoh, M.; Kato, N. A buckwheat protein product suppresses gallstone formation and plasma cholesterol more strongly than soy protein isolate in hamsters. *J Nutr* **2000**, *130*, 1670-1674.
48. Tomotake, H.; Yamamoto, N.; Kitabayashi, H.; Kwakami, A.; Kayashita, J.; Ohinata, H.; Karasawa, H.; Kato, N. Preparation of tartary buckwheat protein product and its improving effect on cholesterol metabolism in rats and mice fed cholesterol-enriched diet. *J Food Sci* **2007**, *72*, S528-S533.
49. Tomotake, H.; Shimaoka, I.; Kayashita, J.; Yokoyama, F.; Nakajoh, M.; Kato, N. Stronger suppression of plasma cholesterol and enhancement of the fecal excretion of steroids by a buckwheat protein product than by a soy protein isolate in rats fed on a cholesterol-free diet. *Biosci Biotech Bioch* **2001**, *65*, 1412-1414.
50. Kayashita, J.; Shimaoka, I.; Nakajoh, M.; Yamazaki, M.; Kato, N. Consumption of buckwheat protein lowers plasma cholesterol and raises fecal neutral sterols in cholesterol-fed rats because of its low digestibility. *J Nutr* **1997**, *127*, 1395-1400.
51. Kayashita, J.; Shimaoka, I.; Nakajoh, M.; Y, A.; Kato, N. Feeding of buckwheat protein extract reduces body fat content in rats. In *current advances in buckwheat research*, proceedings of the 6th international symposium on buckwheat, shinshu, august 24-29, 1995; matano, t., ujihara, a., eds.; shinshu university press: Shinshu, china, 1995; pp 935-940. **1995a**.
52. Kayashita, J.; Shimaoka, I.; Nakajoh, M.; Kato, N. Feeding of buckwheat protein extract reduces hepatic triglyceride concentration, adipose tissue weight, and hepatic lipogenesis in rats. *J Nutr Biochem* **1996**, *7*, 555-559.
53. Kayashita, J.; Shimaoka, I.; Nakajoh, M. Hypocholesterolemic effect of buckwheat protein extract in rats fed cholesterol-enriched diets. *Nutr Res* **1995b**, *15*, 691-698.

54. Hu, Y.Y.; Zhao, Y.; Yuan, L.; Yang, X.B. Protective effects of tartary buckwheat flavonoids on high tmao diet-induced vascular dysfunction and liver injury in mice. *Food Funct* **2015b**, *6*, 3359-3372.
55. Han, S.Y.; Lu, H.; Zhu, L.S.; Liu, S.M.; Jia, X.R.; La, W.Y.; Liang, Y.P. Effect of total flavones of buckwheat seed on lowering serum lipid, glucose and anti-lipid peroxidation. *Chin. Pharmacol. Bull.* **2001**, *17*, 694-696.
56. Qu, Y.; Yasuda, T.; Nakajima, K.; Hiwatashi, A.; Moroi, C.; Sanada, H.; Egashira, Y. Effect of rutin in buckwheat noodle on lipid metabolism in rats. *Food Sci Technol Res* **2013**, *19*, 1011-1018.
57. Zhang, C.; Zhang, R.; Li, Y.M.; Liang, N.; Zhao, Y.; Zhu, H.; He, Z.; Liu, J.; Hao, W.; Jiao, R., *et al.* Cholesterol-lowering activity of tartary buckwheat protein. *J Agr Food Chem* **2017**, *65*, 1900-1906.
58. Higgins, J.; Green, S. Eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.2 [updated september 2009]. The cochrane collaboration. Available from: www.Cochrane-handbook.Org (cited june 2011). **2009**.
59. Goldberg, I.J.; Kako, Y.; Lutz, E.P. Responses to eating: Lipoproteins, lipolytic products and atherosclerosis. *Curr Opin Lipidol* **2000**, *11*, 235-241.
60. Hill, J.O.; Peters, J.C. Environmental contributions to the obesity epidemic. *Science* **1998**, *280*, 1371-1374.
61. Kahn, B.B.; Flier, J.S. Obesity and insulin resistance. *J Clin Invest* **2000**, *106*, 473-481.
62. Williams, G. Obesity and type 2 diabetes: A conflict of interests? *International journal of obesity and related metabolic disorders* **1999**, *23 Suppl 7*, S2-4.
63. Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R.; Collaboration, P.S. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* **2002**, *360*, 1903-1913.
64. Banach, M.; Aronow, W.S. Hypertension therapy in the older adults-do we know the answers to all the questions? The status after publication of the accf/aha 2011 expert consensus document on hypertension in the elderly. *J Hum Hypertens* **2012**, *26*, 641-643.
65. Tighe, P.; Duthie, G.; Vaughan, N.; Brittenden, J.; Simpson, W.G.; Duthie, S.; Mutch, W.; Wahle, K.; Horgan, G.; Thies, F. Effect of increased consumption of whole-grain foods on blood pressure and other cardiovascular risk markers in healthy middle-aged persons: A randomized controlled trial. *American Journal of Clinical Nutrition* **2010**, *92*, 733-740.
66. Seal, C.J.; Brownlee, I.A. Whole-grain foods and chronic disease: Evidence from epidemiological and intervention studies. *P Nutr Soc* **2015**, *74*, 313-319.
67. Coutinho, M.; Gerstein, H.; Wang, Y.; Yusuf, S. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years *Diabetes Care* **1999**, *22*, 233-240.
68. Uwaifo, G.I.; Ratner, R.E. The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. *The American Journal of Medicine* **2003**, *115*, 12-19.
69. Hallfrisch, J.; Behall, K.M. Mechanisms of the effects of grains on insulin and glucose responses. *J Am Coll Nutr* **2000**, *19*, 320s-325s.
70. Liese, A.D.; Roach, A.K.; Sparks, K.C.; Marquart, L.; D'Agostino, R.B.; Mayer-Davis, E.J. Whole-grain intake and insulin sensitivity: The insulin resistance atherosclerosis study. *American Journal of Clinical Nutrition* **2003**, *78*, 965-971.
71. Steffen, L.M.; Jacobs, D.R.; Murtaugh, M.A.; Moran, A.; Steinberger, J.; Hong, C.P.; Sinaiko, A.R. Whole grain intake is associated with lower body mass and greater insulin sensitivity among adolescents. *Am J Epidemiol* **2003**, *158*, 243-250.
72. Sloth, B.; Krog-Mikkelsen, I.; Flint, A.; Tetens, I.; Bjorck, I.; Vinoy, S.; Elmstahl, H.; Astrup, A.; Lang, V.; Raben, A. No difference in body weight decrease between a low-glycemic-index and a high-glycemic-index diet but reduced ldl cholesterol after 10-wk ad libitum intake of the low-glycemic-index diet. *American Journal of Clinical Nutrition* **2004**, *80*, 337-347.

- 753 73. De Rougemont, A.; Normand, S.; Nazare, J.A.; Skilton, M.R.; Sothier, M.; Vinoy, S.; Laville, M.
754 Beneficial effects of a 5-week low-glycaemic index regimen on weight control and
755 cardiovascular risk factors in overweight non-diabetic subjects. *Brit J Nutr* **2007**, *98*, 1288-
756 1298.
- 757 74. Tovar, J.; Nilsson, A.; Johansson, M.; Bjorck, I. Combining functional features of whole-grain
758 barley and legumes for dietary reduction of cardiometabolic risk: A randomised cross- over
759 intervention in mature women. *Brit J Nutr* **2014**, *111*, 706-714.
- 760 75. Fonteles, M.C.; Almeida, M.Q.; Larner, J. Antihyperglycemic effects of 3-o-methyl-d-chiro-
761 inositol and d-chiro-inositol associated with manganese in streptozotocin diabetic rats. *Horm*
762 *Metab Res* **2000**, *32*, 129-132.
- 763 76. Johnston, K.; Sharp, P.; Clifford, M.; Morgan, L. Dietary polyphenols decrease glucose uptake
764 by human intestinal caco-2 cells. *Febs Lett* **2005**, *579*, 1653-1657.
- 765 77. Zhang, Z.-L.; Zhou, M.-L.; Tang, Y.; Li, F.-L.; Tang, Y.-X.; Shao, J.-R.; Xue, W.-T.; Wu, Y.-M.
766 Bioactive compounds in functional buckwheat food. *Food Res. Int.* **2012**, *49*, 389-395.
- 767 78. Kwon, O.; Eck, P.; Chen, S.L.; Corpe, C.P.; Lee, J.H.; Kruhlak, M.; Levine, M. Inhibition of the
768 intestinal glucose transporter glut2 by flavonoids. *Faseb J* **2007**, *21*, 366-377.
- 769 79. Skrabanja, V.; Elmstahl, H.G.M.L.; Kreft, I.; Bjorck, I.M.E. Nutritional properties of starch in
770 buckwheat products: Studies in vitro and in vivo. *J Agr Food Chem* **2001**, *49*, 490-496.
- 771 80. Yusuf, S.; Hawken, S.; Ounpuu, S.; Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.;
772 Pais, P.; Varigos, J., *et al.* Effect of potentially modifiable risk factors associated with
773 myocardial infarction in 52 countries (the interheart study): Case-control study. *Lancet* **2004**,
774 *364*, 937-952.
- 775 81. Lloyd-Jones, D.; Adams, R.J.; Brown, T.M.; Carnethon, M.; Dai, S.; De Simone, G.; Ferguson,
776 T.B.; Ford, E.; Furie, K.; Gillespie, C., *et al.* Heart disease and stroke statistics-2010 update a
777 report from the american heart association. *Circulation* **2010**, *121*, E46-E215.
- 778 82. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering
779 of ldl cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials.
780 *The Lancet* **2010**, *376*, 1670-1681.
- 781 83. Ripsin, C.M.; Keenan, J.M.; Jacobs, D.R., Jr.; Elmer, P.J.; Welch, R.R.; Horn, L.V.; Liu, K.; Turnbull,
782 W.H.; Thye, F.W.; Kestin, M., *et al.* Oat products and lipid lowering: A meta-analysis. *JAMA*
783 **1992**, *267*, 3317-3325.
- 784 84. Christa, K.; Soral-Smietana, M. Buckwheat grains and buckwheat products - nutritional and
785 prophylactic value of their components - a review. *Czech J Food Sci* **2008**, *26*, 153-162.
- 786 85. Dziedzic, K.; Górecka, D.; Kobus-Cisowska, J.; Jeszka, M. Opportunities of using buckwheat in
787 production of functional food. *Nauka Przyroda Technologie* **2010**, *4*, 2-6.
- 788 86. Judd, P.A.; Truswell, A.S. The effect of rolled oats on blood-lipids and fecal steroid-excretion
789 in man. *American Journal of Clinical Nutrition* **1981**, *34*, 2061-2067.
- 790 87. Gordon, T.; Castelli, W.P.; Hjortland, M.C.; Kannel, W.B.; Dawber, T.R. High-density lipoprotein
791 as a protective factor against coronary heart-disease - framingham study. *Am J Med* **1977**, *62*,
792 707-714.
- 793 88. Shinnick, F.L.; Ink, S.L.; Marlett, J.A. Dose response to a dietary oat bran fraction in cholesterol-
794 fed rats. *J Nutr* **1990**, *120*, 561-568.
- 795 89. Story, J.A. Dietary fiber and lipid-metabolism. *P Soc Exp Biol Med* **1985**, *180*, 447-452.
- 796 90. Anderson, J.W.; Siesel, A.E. Hypocholesterolemic effects of oat products. *Advances in*
797 *Experimental Medicine and Biology* **1990**, *270*, 17-36.
- 798 91. Slavin, J.L.; Martini, M.C.; Jacobs, D.R.; Marquart, L. Plausible mechanisms for the
799 protectiveness of whole grains. *American Journal of Clinical Nutrition* **1999**, *70*, 459s-463s.
- 800 92. Escudero, N.L.; Zirulnik, F.; Gomez, N.N.; Mucciarelli, S.I.; Gimenez, M.S. Influence of a protein
801 concentrate from amaranthus cruentus seeds on lipid metabolism. *Exp Biol Med* **2006**, *231*,
802 50-59.

- 803 93. Liu, S.; Manson, J.; Stampfer, M.; Holmes, M.; Hu, F.; Hankinson, S.; Willett, W. Dietary
804 glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-
805 lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women
806 *American Journal Of Clinical Nutrition* **2001**, *73*, 560-566.
- 807 94. Carroll, K.K.; Hamilton, R.M. Effects of dietary-protein and carbohydrate on plasma cholesterol
808 levels in relation to atherosclerosis. *J Food Sci* **1975**, *40*, 18-23.
- 809 95. Carroll, K.K. Hypercholesterolemia and atherosclerosis - effects of dietary-protein. *Fed Proc*
810 **1982**, *41*, 2792-2796.
- 811 96. Terpstra, A.H.; Hermus, R.J.; West, C.E. The role of dietary protein in cholesterol metabolism.
812 *World Review of Nutrition and Dietetics* **1983**, *42*, 1-55.
- 813 97. Pomeranz, Y. Buckwheat - structure, composition, and utilization. *Crc Cr Rev Food Sci* **1983**,
814 *19*, 213-258.
- 815 98. Pomeranz, Y.; Robbins, G.S. Amino-acid composition of buckwheat. *J Agr Food Chem* **1972**, *20*,
816 270-274.
- 817 99. Ikeda, K.; Kishida, M. Digestibility of proteins in buckwheat seed. *Fagopyrum* **1993**, *13*, 21-24.
- 818 100. Eastwood, M.A. The physiological effect of dietary fiber - an update. *Annu Rev Nutr* **1992**, *12*,
819 19-35.
- 820 101. Kritchevsky, D. Dietary fiber. *Annu Rev Nutr* **1988**, *8*, 301-328.
- 821 102. Yiming, Z.; Hong, W.; Linlin, C.; Xiaoli, Z.; Wen, T.; Xinli, S. Evolution of nutrient ingredients in
822 tartary buckwheat seeds during germination. *Food Chem* **2015**, *186*, 244-248.
- 823 103. Kararli, T.T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of
824 humans and commonly used laboratory-animals. *Biopharm Drug Dispos* **1995**, *16*, 351-380.
- 825 104. Ma, Y.; Xiong, Y.L. Antioxidant and bile acid binding activity of buckwheat protein in vitro
826 digests. *J Agr Food Chem* **2009**, *57*, 4372.
- 827 105. Zhou, X.L.; Huang, L.; Tang, W.; Zhou, Y.M.; Wang, Q.; Li, Z.J. A novel buckwheat protein with
828 a beneficial effect in atherosclerosis was purified from fagopyrum tataricum (l.) gaertn. *Arch*
829 *Biol Sci* **2013**, *65*, 767-772.
- 830 106. Holasova, M.; Fiedlerova, V.; Smrcinova, H.; Orsak, M.; Lachman, J.; Vavreinova, S. Buckwheat
831 - the source of antioxidant activity in functional foods. *Food Res. Int.* **2002**, *35*, 207-211.
- 832 107. Fabjan, N.; Rode, J.; Kosir, I.J.; Wang, Z.; Zhang, Z.; Kreft, I. Tartary buckwheat (fagopyrum
833 tataricum gaertn.) as a source of dietary rutin and quercitrin. *J Agr Food Chem* **2003**, *51*, 6452.
- 834 108. Vogrincic, M.; Timoracka, M.; Melichacova, S.; Vollmannova, A.; Kreft, I. Degradation of rutin
835 and polyphenols during the preparation of tartary buckwheat bread. *J Agric Food Chem* **2010**,
836 *58*, 4883-4887.
- 837 109. Kuwabara, T.H., Kh ; Hashimoto, N ; Yamauchi, H ; Shimada, KI ; Sekikawa, M ; Fukushima, M.
838 Tartary buckwheat sprout powder lowers plasma cholesterol level in rats *Journal Of*
839 *Nutritional Science And Vitaminology* **2007**, *53*, 501-507.
- 840 110. Park, S.Y.; Bok, S.H.; Jeon, S.M.; Park, Y.B.; Lee, S.J.; Jeong, T.S.; Choi, M.S. Effect of rutin and
841 tannic acid supplements on cholesterol metabolism in rats. *Nutr Res* **2002**, *22*, 283-295.
- 842 111. Panchal, S.K.; Poudyal, H.; Arumugam, T.V.; Brown, L. Rutin attenuates metabolic changes,
843 nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat
844 diet-fed rats. *J Nutr* **2011**, *141*, 1062-1069.
- 845 112. Choi, I.; Park, Y.; Choi, H.; Lee, E.H. Anti-adipogenic activity of rutin in 3t3-l1 cells and mice fed
846 with high-fat diet. *Biofactors* **2006**, *26*, 273-281.
- 847 113. Kitabayashi H, U.A., Hirose T, Minami M. Varietal differences and heritability for rutin content
848 in common buckwheat, fagopyrum esculentum moench *Breeding Science* **1995**, *45*, 75-79.
- 849 114. Igarashi, K.; Ohmuma, M. Effects of isorhamnetin, rhamnetin, and quercetin on the
850 concentrations of cholesterol and lipoperoxide in the serum and liver and on the blood and
851 liver antioxidative enzyme-activities of rats. *Biosci Biotech Bioch* **1995**, *59*, 595-601.

115. Juzwiak, S.; Wojcicki, J.; Mokrzycki, K.; Marchlewicz, M.; Bialecka, M.; Wenda-Rozewicka, L.; Gawronska-Szklarz, B.; Drozdik, M. Effect of quercetin on experimental hyperlipidemia and atherosclerosis in rabbits. *Pharmacol Rep* **2005**, *57*, 604-609.
116. Odbayar, T.O.; Badamhand, D.; Kimura, T.; Takahashi, Y.; Tsushida, T.; Ide, T. Comparative studies of some phenolic compounds (quercetin, rutin, and ferulic acid) affecting hepatic fatty acid synthesis in mice. *J Agr Food Chem* **2006**, *54*, 8261-8265.
117. Yugarani, T.; Tan, B.K.; Teh, M.; Das, N.P. Effects of polyphenolic natural products on the lipid profiles of rats fed high fat diets. *Lipids* **1992**, *27*, 181-186.
118. Hayek, T.; Fuhrman, B.; Vaya, J.; Rosenblat, M.; Belinky, P.; Coleman, R.; Elis, A.; Aviram, M. Reduced progression of atherosclerosis in apolipoprotein e-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of ldl to oxidation and aggregation. *Arterioscl Throm Vas* **1997**, *17*, 2744-2752.
119. Lauridsen, S.T.; Mortensen, A. Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in watanabe heritable hyperlipidemic rabbits. *Atherosclerosis* **1999**, *142*, 169-178.
120. Enkhmaa, B.S., K ; Katsube, T ; Kitajima, K ; Anuurad, E ; Yamasaki, M ; Yamane, Y. Mulberry (*morus alba* l.) leaves and their major flavonol quercetin 3-(6-malonylglucoside) attenuate atherosclerotic lesion development in ldl receptor-deficient mice *The Journal of Nutrition* **2005**, 729-734.
121. Glasser, G.; Graefe, E.U.; Struck, F.; Veit, M.; Gebhardt, R. Comparison of antioxidative capacities and inhibitory effects on cholesterol biosynthesis of quercetin and potential metabolites. *Phytomedicine* **2002**, *9*, 33-40.
122. Pincemail, J.; Deby, C.; Thirion, A.; de Bruyn-Dister, M.; Goutier, R. Human myeloperoxidase activity is inhibited in vitro by quercetin. Comparison with three related compounds. *Experientia* **1988**, *44*, 450-453.
123. Nicholls, S.J.; Hazen, S.L. Myeloperoxidase, modified lipoproteins, and atherogenesis. *J Lipid Res* **2009**, *50 Suppl*, S346-351.